ERBB3 |
V104L |
Different Mutation |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
V104L |
Different Mutation |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
KRAS |
G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R273C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
L3221P |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
L3221P |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
L3221P |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
L3221P |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
L3221P |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
L3221P |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
D1843Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P1012P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
GNAS |
R201H |
Complete Match |
JAK inhibitor |
Responsive |
CANCER |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FBXW7 |
R465C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R465C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R465C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R465C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
RNF43 |
S720* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
KMT2A |
P3539H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3539H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3539H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3539H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3539H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3539H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ALK |
G1202G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1202G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1202G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1202G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1202G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1202G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1202G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1202G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1202G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1202G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1202G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1202G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1202G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1202G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1202G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1202G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1202G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1202G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1202G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
Y220C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
S796* |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ESR1 |
S106G |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
FANCA |
E1196* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
E1196* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
TP53 |
A159V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
R309G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R309G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ABL1 |
G1060D |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G1060D |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G1060D |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G1060D |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G1060D |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G1060D |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
T125T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
T490M |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T490M |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T490M |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
A811A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A811A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
H829P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
C242R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
AKT3 |
R241Q |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
G187R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G187R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G187R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G187R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G187R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G187R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G187R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G187R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G187R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G187R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G187R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G187R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G187R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G187R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G187R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
E120* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E120* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E120* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E120* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
P151S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
E174* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
BRD4 |
V242V), BRD4 MUT* (P243P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ARID1A |
Q538* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q538* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q538* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q538* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
R589H |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R589H |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R589H |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R589H |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R589H |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R589H |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
KRAS |
Q61H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61H |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61H |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61H |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61H |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61H |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61H |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61H |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61H |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
CDKN2A |
splice_donor_variant |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_donor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_donor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
splice_donor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_donor_variant |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
M472I |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
M472I |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
M472I |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
M472I |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
M472I |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
M472I |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KRAS |
G12R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R282W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
M636V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH2 |
A21S |
Different Mutation |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
A21S |
Different Mutation |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
A21S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
I255T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BCR |
M288R |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
M288R |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
M288R |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M288R |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M288R |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
M288R |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
TP53 |
splice_donor_variant |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
splice_donor_variant |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
splice_donor_variant |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_donor_variant |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
M1478T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1478T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M1478T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M1478T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M1478T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1478T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1478T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M1478T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1478T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1478T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M1478T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M1478T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M1478T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1478T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1478T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1478T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M1478T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M1478T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1478T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
A161D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A161D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A161D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A161D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A161D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A161D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A161D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A161D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A161D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CRLF2 |
P224L |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
P224L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH2 |
H2194H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTCH1 |
Q938* |
Complete Match |
Vismodegib (SHH inhibitor) |
Responsive |
BCC, MB |
FDA guidelines |
PTCH1 |
Q938* |
Complete Match |
Foretinib (MET inhibitor) |
Responsive |
MB |
Pre-clinical |
PTCH1 |
Q938* |
Complete Match |
SMO inhibitor |
Responsive |
MB |
Pre-clinical |
TP53 |
A159D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Q321* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12C |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12C |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12C |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12C |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12C |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12C |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12C |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R248W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
L2457V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L2457V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCR |
R22L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
R22L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
R22L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R22L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R22L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
R22L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
CDKN2A |
R80* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R80* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2D |
C5123* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
G3884F |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G3884F |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G3884F |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G3884F |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G3884F |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G3884F |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KRAS |
G12A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12A |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12A |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12A |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12A |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12A |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12A |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12A |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
C238Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
P684P |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P684P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684P |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P684P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684P |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
CHEK2 |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
CHEK2 |
splice_donor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
PML |
A93G |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
A93G |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
A93G |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
FGFR2 |
G131R |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
G131R |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
L3462P), MLL MUT* (I2918V |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
F1148F), BCR MUT* (G187G |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
KRAS |
G12I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12I |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12I |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12I |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12I |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12I |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12I |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12I |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12I |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ARID1A |
Q503* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R306* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R306* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R306* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R306* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R306* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R306* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R306* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R306* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R306* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R306* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
Y2619C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Y2619C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Y2619C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Y2619C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Y2619C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Y2619C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
IDH1 inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
AG-120 (IDH1 inhibitor) |
Responsive |
G |
Early trials |
IDH1 |
R132L |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH1 |
R132L |
Complete Match |
Ivosidenib (IDH1 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
BCL2 inhibitor |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
BCL2 inhibitor (BCL2 inhibitor) |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
S1500* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
S1500* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
S1500* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
S1500* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
S1500* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
R1942W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1942W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1942W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1942W |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1942W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
T518M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T518M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
Q61R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61R |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61R |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NTRK1 |
R119R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R119R |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R119R |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R119R |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TMPRSS2 |
E297K |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
E297K |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
TP53 |
G245S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
F200S |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
F200S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
F200S |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
T43S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E322K |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E322K |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E322K |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
LRP1B |
E3875* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
E3875* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
PBRM1 |
R534* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
R534* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
R534* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
R534* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R534* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EPHA3 |
C306* |
Different Alteration |
EPHA3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
FGFR3 |
V393V |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
V393V |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
V393V |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
C176S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
G438G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P267P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ERBB4 |
C156C |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
M237I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M237I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M237I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M237I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M237I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M237I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M237I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M237I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M237I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
I681N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
W1157C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
W1157C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
P1112P |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P1112P |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P1112P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P1112P |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1112P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1112P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P1112P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1112P |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1112P |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P1112P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P1112P |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P1112P |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112P |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112P |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1112P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P1112P |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P1112P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1112P |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
JAK3 |
Q501H |
Complete Match |
JAK inhibitor |
Responsive |
MKB |
Pre-clinical |
JAK3 |
Q501H |
Different Mutation |
JAK inhibitor |
Responsive |
LY |
Pre-clinical |
PBRM1 |
Y387* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Y387* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Y387* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Y387* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Y387* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q167* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q167* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q167* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q167* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q167* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q167* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q167* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q167* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
P2216L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P2216L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FGFR2 |
F646V |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
F646V |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
R267W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R267W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R267W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R267W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R267W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R267W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R267W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R267W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R267W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
G266V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
P1365L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P1365L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P1365L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P1365L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P1365L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P1365L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
P281L |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
P281L |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
P281L |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
P281L |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
P281L |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
P281L |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
P281L |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P281L), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
P281L), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
P281L), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
P281L), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
FGFR2 |
P814T |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
P814T |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
K132Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R2039H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R2039H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH2 |
CdsStartSNV |
Different Mutation |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
CdsStartSNV |
Different Mutation |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
CdsStartSNV |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
K539K |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ALK |
M233V |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M233V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M233V |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M233V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M233V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M233V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M233V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M233V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M233V |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M233V |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M233V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M233V |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M233V |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M233V |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M233V |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M233V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M233V |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M233V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M233V |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
S215I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S215I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S215I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S215I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S215I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S215I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S215I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S215I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
L745L |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
L745L |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
L745L |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
L745L |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
PML |
R280L |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
R280L |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
R280L |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
MSH3 |
splice_donor_variant |
Complete Match |
DNA-PKc inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH2 |
A20G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
G2152G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2152G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
R79* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
R79* |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
BRD4 |
Q1298Q |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRCA2 |
R2494* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
R2494* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2494* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
R2494* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
R2494* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
R2494* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
R2494* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
R2494* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2494* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2494* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2494* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2494* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2494* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2494* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
S127F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S127F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S127F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S127F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S127F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S127F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S127F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S127F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NF2 |
Y144* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
Y144* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
Y144* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
Y144* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
Y144* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
Y144* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
Y144* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
Y144* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
Y144* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y144* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y144* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NOTCH2 |
H1160R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
N685T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N685T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q546* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q546* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q546* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q546* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PDGFRA |
E715K |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PML |
T833T |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
T833T |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
T833T |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
HIF1A |
R463* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
CDKN2A |
E69* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E69* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E69* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E69* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E69* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E69* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E69* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E69* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
MET |
Y1252Y), MET MUT* (T200A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NTRK3 |
G233G |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G233G |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G233G |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
G89S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G89S |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G89S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G89S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
JAK2 |
T108A |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q1134R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q1134R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FGFR3 |
G65R |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
G65R |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
G65R |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
FGFR3 |
K592K |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
K592K |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
K592K |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
H179R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
L1012L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCR |
S459L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
S459L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
S459L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
S459L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
S459L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
S459L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |